Arrowg+ard Blue¿ MAC" Two-Lumen Central Venous Access Kit for use with 7.5 - 8 Fr. Catheters REF ...
FDA Device Recall #Z-1917-2026 — Class II — March 11, 2026
Recall Summary
| Recall Number | Z-1917-2026 |
| Classification | Class II — Moderate risk |
| Date Initiated | March 11, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | ARROW INTERNATIONAL, LLC |
| Location | Morrisville, NC |
| Product Type | Devices |
| Quantity | 95 |
Product Description
Arrowg+ard Blue¿ MAC" Two-Lumen Central Venous Access Kit for use with 7.5 - 8 Fr. Catheters REF ASK-21142-DMC UDI code: (01)10801902218930(17)270630(11)251211(10)33F25M0671 The MAC Multi-Lumen Central Venous Access Device with Arrowg+ard Blue technology permits short-term (<30 days) venous access and catheter introduction to the central circulation. It may be inserted into the jugular, subclavian, or femoral veins. The Arrowg+ard technology is intended to help provide protection against catheterrelated infections. Clinical data have not been collected that demonstrate the use of the Arrowg+ard antimicrobial surface in decreasing catheter-related infections for this device. It is not intended to be used as a treatment for existing infections, nor is it indicated for long-term use.
Reason for Recall
Due to receiving a notice from a supplier that the liquid adhesive was incorrectly manufactured
Distribution Pattern
U.S. Nationwide distribution in the states of AZ, CA, GA, MA, ME, MI, OR, PA, and VA.
Lot / Code Information
Product Code: ASK-21142-DMC UDI code: (01)10801902218930(17)270630(11)251211(10)33F25M0671 Batch Number: 33F25M0671
Other Recalls from ARROW INTERNATIONAL, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2157-2026 | Class I | Arrow-Clark VectorFlow Antegrade Chronic Hemodi... | Apr 10, 2026 |
| Z-2156-2026 | Class I | Arrow Edge Hemodialysis Catheterization Product... | Apr 10, 2026 |
| Z-2159-2026 | Class I | NextStep Antegrade Chronic Hemodialysis Cathete... | Apr 10, 2026 |
| Z-2158-2026 | Class I | Cannon II Plus Hemodialysis Catheter, REF: CS-1... | Apr 10, 2026 |
| Z-1916-2026 | Class II | MAC" Two-Lumen Central Venous Access Kit for us... | Mar 11, 2026 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.